Lilly (Eli) & Co, founded in 1876 and headquartered in Indianapolis, Indiana, is a global leader in pharmaceutical innovation dedicated to creating life-changing medicines. The company specializes in developing innovative treatments across several therapeutic areas, including oncology, diabetes, and immunology, with a commitment to improving patient outcomes.
Company overview and issue history are AI generated, and should not be cited or relied on without verification.
Lilly has been actively issuing bonds since the 1980s, with significant issuances that reflect its robust capital strategy. One notable issuance was the $3 billion debt offering in April 2021, which was aimed at funding general corporate purposes and strengthening its balance sheet. As of October 2023, Lilly's bonds currently yield around 3.5%, which is competitive compared to the pharmaceutical industry's average yield. Furthermore, Lilly's bonds typically feature attractive callable provisions, allowing the company the flexibility to refinance at lower rates if market conditions change.